Royalty PharmaMEX:RPRXN 72 Dividend Payout Ratio is 0.28 as of Mar. 2026, which is 39% below its 10-year median of 0.46. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review. Among 134 Biotechnology companies, Royalty Pharma ranks worse than 53.73% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Royalty Pharma's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.28.
The historical rank and industry rank for Royalty Pharma's Dividend Payout Ratio or its related term are showing as below:
During the past 9 years, the highest Dividend Payout Ratio of Royalty Pharma was 0.55. The lowest was 0.33. And the median was 0.46.
MEX:RPRXN's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 12 months, Royalty Pharma's average Dividends Per Share Growth Rate was 5.30% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 5.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 18.90% per year.
During the past 9 years, the highest 3-Year average Dividends Per Share Growth Rate of Royalty Pharma was 38.70% per year. The lowest was 5.00% per year. And the median was 7.30% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Royalty Pharma (MEX:RPRXN) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Royalty Pharma Dividend Payout Ratio Related Terms
Royalty Pharma Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RPRXN vs BNTX, INSM, ROIV: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Royalty Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Royalty Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (MEX:RPRXN) has a Dividend Payout Ratio of 0.28 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Royalty Pharma and its competitors. This is 39% below median its historical median of 0.46. Over the past decade, Royalty Pharma's Dividend Payout Ratio has ranged from 0.33 to 0.55. According to the industry distribution chart, Royalty Pharma ranks #72 out of 134 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Royalty Pharma's Dividend Payout Ratio too high?
Royalty Pharma's current Dividend Payout Ratio of 0.28 is 39% below median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 0.55. The Biotechnology industry median Dividend Payout Ratio is 0.45. Royalty Pharma's value of 0.28 is 37.1% below this industry median. Based on the distribution chart, Royalty Pharma ranks #72 out of 134 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Dividend Payout Ratio compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #72 out of 134 companies for Dividend Payout Ratio. This places Royalty Pharma in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. Royalty Pharma's value of 0.28 is 37.1% below this benchmark. Historically, Royalty Pharma's own Dividend Payout Ratio has ranged from 0.33 to 0.55 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.45, Royalty Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Royalty Pharma's current Dividend Payout Ratio of 0.28 is 37.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Dividend Payout Ratio is 0.28, which is 39% below median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Dividend Payout Ratio of 0.28. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Dividend Payout Ratio is 0.28, which is 39% below median its 10-year median of 0.46 and 37.1% below the Biotechnology industry median of 0.45. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Dividend Payout Ratio is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.
Key valuation signals for MEX:RPRXN:
Dividend Payout Ratio: 0.28 (39% below median its 10-year median of 0.46)
GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
Industry Position: 37.1% below the Biotechnology median (#72 of 134)
No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for MEX:RPRXN
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RPRXN has been successfully added to your 
